Company profile for Neok Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NEOK Bio is a science-driven oncology biotechnology company focused on developing next-generation bispecific antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Backed by world-leading antibody engineering capabilities from ABL Bio, NEOK is advancing differentiated bispecific ADCs that target two complementary antigens to enhance efficacy and safety in solid tumors. The company leverages its proprietary pl...
NEOK Bio is a science-driven oncology biotechnology company focused on developing next-generation bispecific antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. Backed by world-leading antibody engineering capabilities from ABL Bio, NEOK is advancing differentiated bispecific ADCs that target two complementary antigens to enhance efficacy and safety in solid tumors. The company leverages its proprietary platform and deep scientific expertise to unlock the full potential of ADC therapies and deliver meaningful benefits to patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
260 Sheridan Avenue, Suite 200, Palo Alto, CA 94306
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-03-27/biocytogen-announces-fda-ind-clearance-for-partner-neok-bio-s-neok002-targeting-solid-tumors-1

PHARMIWEB
27 Mar 2026

https://www.businesswire.com/news/home/20260302686948/en/NEOK-Bio-Secures-FDA-IND-Clearance-for-NEOK002-a-Novel-EGFRMUC1-Bispecific-ADC-for-Treatment-of-Solid-Tumors

BUSINESSWIRE
02 Mar 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty